Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2
pharmaphorum
DECEMBER 21, 2022
Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. In its third-quarter update, the Danish drugmaker reported sales of Rybelsus reached DKK 7.25
Let's personalize your content